A_DT
novel_JJ
mutation_NN
in_IN
the_DT
coding_VBG
sequence_NN
of_IN
the_DT
FY_NN
\*_NN
B_NN
allele_NN
of_IN
the_DT
Duffy_NN
chemokine_NN
receptor_NN
gene_NN
is_VBZ
associated_VBN
with_IN
an_DT
altered_JJ
erythrocyte_NN
phenotype_NN
._.

The_DT
Duffy_NN
blood_NN
group_NN
system_NN
is_VBZ
of_IN
clinical_JJ
and_CC
biological_JJ
significance_NN
._.

Antibodies_NNS
to_TO
Duffy_NN
antigens_NNS
are_VBP
responsible_JJ
for_IN
some_DT
cases_NNS
of_IN
transfusion_NN
incompatibility_NN
and_CC
newborn_JJ
hemolytic_JJ
disease_NN
._.

The_DT
Duffy_NN
protein_NN
is_VBZ
a_DT
receptor_NN
for_IN
the_DT
Plasmodium_NN
vivax_NN
erythrocyte-binding_JJ
protein_NN
and_CC
is_VBZ
also_RB
a_DT
receptor_NN
for_IN
various_JJ
chemokines_NNS
-LRB-_-LRB-
thus_RB
renamed_VBG
Duffy_NN
Antigen_NN
Receptor_NN
for_IN
Chemokines_NNS
-LCB-_-LRB-
DARC_NN
-RCB-_-RRB-
-RRB-_-RRB-
._.

The_DT
two_CD
Duffy_NN
polymorphic_JJ
antigens_NNS
,_,
Fya_NN
and_CC
Fyb_NN
-LRB-_-LRB-
coded_VBN
by_IN
the_DT
FY_NN
\*_NN
A_NN
and_CC
FY_NN
\*_NN
B_NN
alleles_NNS
-RRB-_-RRB-
,_,
are_VBP
present_JJ
on_IN
erythrocyte_NN
membranes_NNS
._.

The_DT
Fy_NN
-LRB-_-LRB-
a-b_NN
-_NN
-RRB-_-RRB-
phenotype_NN
is_VBZ
the_DT
predominant_JJ
one_CD
in_IN
populations_NNS
of_IN
black_JJ
people_NN
and_CC
also_RB
occurs_VBZ
in_IN
other_JJ
populations_NNS
,_,
including_VBG
some_DT
non-Ashkenazi_JJ
Jewish_JJ
groups_NNS
._.

The_DT
Fy_NN
-LRB-_-LRB-
a-b_NN
-_NN
-RRB-_-RRB-
phenotype_NN
has_VBZ
been_VBN
associated_VBN
with_IN
a_DT
mutation_NN
in_IN
the_DT
FY_NN
\*_NN
B_NN
promoter_NN
at_IN
the_DT
GATA_NN
box_NN
that_WDT
abolishes_VBZ
the_DT
expression_NN
of_IN
erythrocyte_NN
Duffy_NN
protein_NN
._.

We_PRP
describe_VBP
here_RB
a_DT
novel_JJ
mutation_NN
,_,
present_JJ
in_IN
the_DT
FY_NN
\*_NN
B_NN
coding_VBG
sequence_NN
-LRB-_-LRB-
271C_NN
--_:
&gt;_JJR
T_NN
-RRB-_-RRB-
,_,
that_WDT
is_VBZ
associated_VBN
with_IN
some_DT
Fy_NN
-LRB-_-LRB-
b_NN
-_:
-RRB-_-RRB-
phenotypes_NNS
among_IN
non-Ashkenazi_JJ
Jews_NNS
and_CC
among_IN
Brazilian_JJ
blacks_NNS
._.

The_DT
mutation_NN
is_VBZ
present_JJ
in_IN
Fy_NN
-LRB-_-LRB-
b_NN
-_:
-RRB-_-RRB-
individuals_NNS
,_,
who_WP
have_VBP
wild-type_JJ
FY_NN
\*_NN
B_NN
GATA_NN
and_CC
carry_VBP
the_DT
previously_RB
described_VBN
304G_NN
--_:
&gt;_JJR
A_DT
substitution_NN
._.

The_DT
271C_NN
--_:
&gt;_JJ
T_NN
and_CC
304G_JJ
--_:
&gt;_JJR
A_NN
can_MD
be_VB
identified_VBN
by_IN
restriction_NN
enzyme-generated_JJ
restriction_NN
fragment_NN
length_NN
polymorphisms_NNS
._.

The_DT
271C_NN
--_:
&gt;_JJR
T_NN
substitution_NN
represents_VBZ
a_DT
considerable_JJ
change_NN
in_IN
chemical_JJ
nature_NN
-LRB-_-LRB-
Arg91_NN
--_:
&gt;_JJR
Cys_CD
-RRB-_-RRB-
,_,
one_CD
which_WDT
may_MD
affect_VB
the_DT
antigenic_JJ
determinants_NNS
of_IN
DARC_NN
,_,
and_CC
thus_RB
be_VB
of_IN
clinical_JJ
significance_NN
._.

The_DT
mutation_NN
may_MD
have_VB
implications_NNS
for_IN
some_DT
physiological_JJ
roles_NNS
of_IN
DARC_NN
and_CC
be_VB
of_IN
interest_NN
in_IN
malaria_NN
research_NN
and_CC
in_IN
studies_NNS
of_IN
population_NN
genetics_NNS
._.

